Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
EDMONTON, Alberta, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V:QPT) (“Quest” or the “Company”) today announced the results of its October 8, 2024 annual general meeting of...
Quest PharmaTech Inc. (TSX-V:QPT) (“Quest” or the “Company”), a pharmaceutical company developing and commercializing products to improve the quality of life, today announced the sale of its...
Quest PharmaTech to Market and Distribute Premium Anti-Wrinkle Skin Care Product, Bellus Skin™; Dr. Jacqueline Shan, Creator of COLD FX®, to Assist PR Newswire EDMONTON, Oct. 22, 2014...
Quest PharmaTech Completes Patient Enrollment in Phase IIb Study of Oregovomab for the Immunotherapy of Ovarian Cancer PR Newswire EDMONTON, June 9, 2014 TSX Venture: QPT EDMONTON, June 9, 2014...
Quest PharmaTech strengthens its Antibody Immunotherapy Technology by licensing anti-MUC1 IgE Technology from Stanford University; Researchers to present late-breaking data at the 28th Annual...
Quest PharmaTech Establishes Joint Venture with Korean-Based AD Biotech Co., Ltd. to Develop Immunotherapeutic Products for Cancer PR Newswire EDMONTON, July 23, 2013 TSX Venture: QPT EDMONTON...
Quest PharmaTech Signs Exclusive License Agreement with UCLA for anti - PSA IgE Technology; UCLA researchers to present anti - PSA IgE preclinical data at the 2013 American Association for Cancer...
Quest PharmaTech Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Cancer in Italy and the U.S. #ReleaseContent TABLE {...
Quest PharmaTech Acquires Immunoglobulin E Technology to Strengthen its Combination Therapy Approach for the Treatment of Cancer PR Newswire EDMONTON, Oct. 2, 2012 TSX Venture: QPT EDMONTON, Oct...
Quest PharmaTech Updates Progress of Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in Italy PR Newswire EDMONTON, July 10, 2012 TSX Venture: QPT EDMONTON, July 10, 2012...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.005 | -14.2857142857 | 0.035 | 0.035 | 0.03 | 64213 | 0.0317255 | CS |
| 4 | 0 | 0 | 0.03 | 0.035 | 0.025 | 68308 | 0.02846578 | CS |
| 12 | 0.005 | 20 | 0.025 | 0.035 | 0.02 | 50947 | 0.02803849 | CS |
| 26 | 0.01 | 50 | 0.02 | 0.04 | 0.015 | 37821 | 0.02431959 | CS |
| 52 | -0.03 | -50 | 0.06 | 0.07 | 0.015 | 29374 | 0.02918631 | CS |
| 156 | -0.065 | -68.4210526316 | 0.095 | 0.165 | 0.015 | 21485 | 0.0603512 | CS |
| 260 | -0.095 | -76 | 0.125 | 0.32 | 0.015 | 25123 | 0.09611393 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
